Skip to main content

Table 2 The baseline characteristics of individual study

From: Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia

Study Group Age (years) BMI (kg/m2) PV (ml) PSA (ng/ml) IPSS Qmax (ml/s) PVR (ml)
Hong et al. (2010) [20] Combination 66.60 ± 7.10 24.90 ± 3.00 ≥ 30 3.0 ± 3.90 >  7 <  15 unmentioned
Tamsulosin 65.70 ± 8.50 24.60 ± 2.30 2.6 ± 2.30
Joo et al. (2012) [21] Combination 65.85 ± 7.77 unmentioned 37.26 ± 13.22 1.77 ± 1.40 19.94 ± 6.14 11.13 ± 5.08 49.16 ± 23.52
Tamsulosin 65.79 ± 8.87 36.63 ± 13.16 1.70 ± 1.23 19.95 ± 5.54 11.32 ± 5.77 49.19 ± 22.04
Roehrborn et al. (2014) [22] Combination 66.00 ± 7.05 unmentioned 54.7 ± 23.51 4.00 ± 2.05 16.60 ± 6.35 10.90 ± 3.61 68.20 ± 66.12
Tamsulosin 66.20 ± 7.00 55.8 ± 24.18 4.00 ± 2.08 16.40 ± 6.10 10.70 ± 3.66 67.70 ± 65.14
Roehrborn et al. (2015) [23] Combination 66.30 ± 7.78 27.28 ± 3.53 51.0 ± 18.17 3.90 ± 2.00 13.20 ± 4.06 unmentioned unmentioned
Tamsulosin 66.20 ± 7.34 27.94 ± 3.77 52.6 ± 19.57 3.70 ± 1.91 12.90 ± 3.95
Choi et al. (2016) [24] Combination 61.86 ± 1.26 unmentioned 41.05 ± 2.67 1.31 ± 0.15 20.04 ± 0.62 11.81 ± 0.29 31.08 ± 2.76
Tamsulosin 61.94 ± 1.23 40.34 ± 1.43 1.35 ± 0.12 19.09 ± 0.60 11.40 ± 0.38 31.00 ± 3.44
  1. Data presented as mean ± SD
  2. IPSS International Prostate Symptom Score, Qmax maximum urine flow rate, PSA Prostate Specific Antigen, PV Prostate Volume, PVR Post-Void Residual, BMI Body Mass Index